NMPA / BCI / 2026-07-24
China BCI Regulatory Standards Report
A source-linked reading of the 2026 Chinese BCI classification guidance, proposed standards, and product-boundary implications.
DECISION BOUNDARY
What the new documents do and do not establish
The four items are concurrent classification conditions, not four mandatory standards. Proposed submissions are not effective standards; GB/T and YY/T entries in this dossier are recommended standards unless a source says otherwise.
Four concurrent classification conditions
- Measure neural signals produced by the central nervous system, including brain and spinal cord.
- Decode in real time and apply the command directly to the primary intended use.
- Provide real-time bidirectional interaction with an external assistive or diagnostic/therapeutic device, or closed-loop feedback.
- Achieve a clinical effect of improving, restoring, or replacing a central nervous system function.
Exact exclusions and wording limits
- Peripheral nerve, EMG, and ECG signals are outside this four-condition definition.
- Collection alone or one-way stimulation alone does not satisfy all four conditions.
- The guidance does not require AI, millisecond thresholds, or a complete bidirectional closed loop; the third condition uses “or”.
Next actions by role
Registration team
Confirm intended use, the four conditions, classification candidates, and evidence gaps before fixing a clinical plan.
Hospital research
Resolve ethics, participant protection, data processing, and device-status boundaries before enrollment.
Industry team
Map recommended standards into engineering practice without presenting them as statutory approval gates.
Investment team
Verify the announcement, attachments, classification, clinical evidence, and registration status rather than treating policy signals as approval evidence.
Dossier source index
Controlled downloads
Full controlled report
Data cutoff: 2026-07-24. AI-assisted translation; not an official legal translation. The original Chinese instrument controls.
Bottom Line: Four Conditions Exist, but They Are Not Four Mandatory Standards
Fact NMPA Announcement No. 24 of 2026 was published and took effect on 2026-06-30. It issued the Guiding Principles for Classification of Brain-Computer Interface Medical Device Products and the Guiding Principles for Generic Naming of Brain-Computer Interface Medical Devices. The classification attachment has four concurrent technical conditions. They are classification-boundary conditions, not four mandatory standards. R001, R004 S0216 S0217
Fact The four conditions must all be present: measuring neural signals generated by the central nervous system (brain and spinal cord); real-time decoding with instructions directly used for the principal intended purpose; real-time two-way interaction or closed-loop feedback between the central nervous system and an external assistive or diagnostic/therapeutic device; and a clinical effect such as improving, restoring, or replacing central nervous function. R004 S0217 S0219
| Condition | Official wording point | Plain language | Official exclusion or boundary | Difference from circulating claim |
|---|---|---|---|---|
| 1 | Neural signals generated by the central nervous system (brain and spinal cord) | Not every body electrical signal | Peripheral nerve, electromyography, or electrocardiography is outside this condition | Not “all neural or physiological signals” |
| 2 | Real-time decoding with instructions directly used for the principal intended purpose | The result directly drives the main use | Real time is a clinically compliant continuous workflow without external intervention; later offline analysis does not qualify | Not merely “uses an algorithm” |
| 3 | Real-time two-way interaction or closed-loop feedback | Either route can satisfy the condition | Collection alone or one-way stimulation does not meet all four conditions | Do not delete “or” or add a millisecond threshold |
| 4 | Improving, restoring, or replacing central nervous function and similar clinical effects | The main use targets a clinical effect | Non-medical enhancement, entertainment, or daily assistance is not automatically within this definition | Not every human-machine interaction is medical BCI |
Fact The attachment defines real-time decoding as follows: the device operates in a defined, continuous time stream and, within a time frame that meets clinical requirements, synchronously converts central nervous signals into device-control instructions. The decoding process is an inseparable continuous part of the medical device's clinical-function workflow, does not depend on external intervention, and produces instructions directly used to achieve the product's principal intended purpose. The text sets no uniform millisecond threshold. R004, R006 S0217
Fact Static MRI, image segmentation, and cosmetic relaxation are not official named examples; they must not be reverse-engineered into an official exclusion list. The four conditions do not require AI or a millisecond threshold. The classification attachment aligns its use of “artificial intelligence technology” with the scope of the Artificial Intelligence Medical Device Registration Review Guidance, and AI affects classification only in the specific route stated below. R005, R006 S0217 S0219
Inference “Four conditions exist” is accurate. “Four mandatory NMPA standards released on 2026-06-30” changes the legal character of the material and omits the product-specific classification analysis. R001, R005 S0216 S0219
Beginner's Guide: Different Documents Do Not Have the Same Legal Effect
Fact Laws, regulations, rules, guidance, recommended standards, notices, submission notices, and clinical papers have different effects. State Council Order No. 739 supplies the general medical-device framework; Order No. 47 covers registration and filing; Announcement No. 24 issues guidance; GB/T and YY/T are recommended standards; a submission notice is not a final standard. R010, R002, R003, R007 S0208 S0209 S0207 S0220
Recommendation State each document's type, date, effective date or notice period, and scope before using it in a product or investment claim.
Timeline: Publication, Consultation, and Effectiveness Must Not Be Mixed
Fact Announcement No. 24 was signed on 2026-06-29 and published and effective on 2026-06-30. GB/T 47023-2026 and GB/T 47127-2026 were published on 2026-01-28 and take effect on 2026-08-01; GB/T 47346-2026 was published on 2026-03-31 and takes effect on 2026-10-01. All three are recommended national standards. R001, R003 S0216 S0204 S0205 S0206
Fact The MIIT dynamic platform lists five submissions under their complete official Chinese titles: 2024-0571T-YD《脑机接口信息系统 脑电数据格式要求》 (BCI information system: EEG data format requirements); 2025-0542T-YD《时间同步网工程技术规范》 (technical specification for time-synchronization network engineering); 2021-0227T-YD《工业建筑信息通信综合布线系统工程技术规范》 (technical specification for information and communications integrated cabling systems in industrial buildings); 2023-1784T-YD《切片分组传送网工程技术规范》 (technical specification for sliced packet transport network engineering); and 2023-0987T-YD《无线通信设备电磁兼容性要求和测量方法 第14部分：甚小孔径终端和交互式卫星地球站设备（在固定卫星业务中工作频率范围为4GHz～30GHz）》 (EMC requirements and measurement methods for radio equipment, Part 14, covering the stated VSAT and interactive satellite earth-station equipment). Only 1/5 directly concerns BCI. All five are submissions under public notice, not effective standards. R002 S0207 MIIT dynamic platform
Inference The useful 4/5/3 shorthand means four classification conditions, five submission drafts, and three recommended GB/T standards, not one group of mandatory BCI rules.
Announcement No. 24 and Its Two Attachments: Claim-by-Claim Check
Fact The exact announcement title includes “two medical-device product guiding principles.” The NMPA announcement page is the original publication page; the classification and generic-naming DOCX files are official Shanghai medical-products-administration mirror attachments. The generic-naming attachment is guidance rather than a mandatory regulation and allows other compliant methods. R001, R006 S0216 S0217 S0218
Fact The four classification conditions do not require use of AI and do not specify a millisecond-level threshold. The third condition uses “or”: real-time two-way interaction or closed-loop feedback. This does not mean AI never affects classification: for the specific non-invasive stroke limb-motor rehabilitation route, no AI is II Class 19-00, while use of AI falls within the other-rehabilitation III Class 19-00 route. Mere collection or one-way stimulation does not meet all four conditions. R005, R006 S0217 S0219
Recommendation Quote the short condition, source, and boundary rather than reproducing either attachment in full.
Classification Routes: Class II and III Depend on Product Facts
Fact The official interpretation identifies III Class 12-00 for invasive/implantable products; III Class 09-00 for non-invasive disease treatment; III Class 19-00 for functional substitution; II Class 19-00 for the specified stroke limb-motor rehabilitation route without AI; III Class 19-00 when AI is used in that route; and III Class 19-00 for other rehabilitation. That AI distinction is limited to this classification route, not a universal AI requirement in the four conditions. Actual intended use and technical features still control. R005 S0217 S0219
Inference Non-invasive, interventional, and implantable designs cannot share one evidence plan. Invasiveness, stimulation, feedback, software, cybersecurity, and intended clinical effect change the analysis.
Standards and Submission Notices: Three GB/T, Five Drafts, and Two YY/T
Fact GB/T 47023-2026 addresses reference architecture, GB/T 47127-2026 multi-modal data format, and GB/T 47346-2026 visual-evoked-potential data coding and decoding. They are recommended national standards. R003 S0204 S0205 S0206
Fact YY/T 1987-2025 is a terminology standard effective 2026-01-01. YY/T 1996-2025 is a recommended test-method standard for sensing and response of closed-loop implantable neurostimulators, effective 2027-10-01. Neither creates a universal four-condition mandatory definition. R007 S0220 S0221
General Medical Device Obligations and Three Product Routes
Fact General medical-device, clinical-evaluation, clinical-trial, software, and cybersecurity obligations continue to apply when applicable; BCI use neither creates a universal exemption nor proves one uniform trial route. R010 S0208 S0209 S0170 S0171 S0188 S0189
Inference Non-invasive products usually require close review of treatment claims, software algorithms, signal quality, usability, and cybersecurity. Interventional products add access-related risk, procedural considerations, and long-term follow-up. Implantable products also require evidence planning for implant materials, electrical safety, biocompatibility, stimulation risk, durability, and closed-loop failure modes. These are risk-planning considerations, not classification conclusions for a particular product.
Recommendation For each route, maintain traceable records for clinical evaluation, the software lifecycle, cybersecurity, data governance, risk management, usability, and post-market monitoring.
Next Steps for Four Audiences
Recommendation Registration teams should freeze intended use and classification candidates first. Hospital researchers should establish ethics, participant protection, data, and device-status boundaries. Industry teams should convert recommended standards into engineering controls without calling them statutory duties. Investors should separately verify announcements, classification, clinical evidence, and registration status.
Clinical Evidence, Data, and Ethics: Credible but Limited
Fact S0194 is a Chinese multicenter RCT at 17 centers reporting n=296: FMA-UE change 13.17 versus 9.83, difference 3.35 (95% CI 1.05-5.65, p=0.0045), and adverse events 22.00% versus 21.23%. It was Open-label, and registry actual enrollment 300 differs from the paper's 296; it cannot establish effectiveness for every BCI device or setting. R010 S0194
Fact S0195 pooled 21 RCTs and n=886 patients: FMA-UE MD 3.69 (95% CI 2.41-4.96, I2=70%), ARAT MD 2.04, and MBI was not significant. Heterogeneity, infeasible blinding, possible publication bias, and small subgroups limit inference. This is not a registration approval or evidence of universal effectiveness. R010 S0195
Fact PIPL, the Data Security Law, the Cybersecurity Law, the BCI research ethics guideline, and the 2026 AI science-and-technology ethics review and services measures apply by actual processing, system, and research facts; they are not medical-device classification rules. R020 S0164 S0211 S0212 S0213 S0214
Limited FDA/EU Comparison
Fact FDA implanted-BCI guidance availability and EU MDR are limited comparators. Neither is a Chinese approval or substitutes for Chinese legal analysis. R030 S0037 S0215
Action Checklist, Common Misreadings, and Update Triggers
Recommendation Verify Announcement No. 24 and its attachments; record each condition; select and recheck classification candidates; distinguish publication, notice, and effectiveness; maintain clinical, software, cybersecurity, data-governance, and post-market evidence; cite the original source for every external claim.
Fact The following claims exceed the sources: “four conditions are four mandatory standards,” “AI or millisecond performance is mandatory,” “the third condition requires complete two-way closed loop,” “five submission drafts are effective,” and “a clinical paper is an approval.” R001, R002, R003, R006, R007 S0216 S0207 S0221
Recommendation Recheck on amendment of the announcement or attachments, classification catalogue change, finalization of a submission draft, GB/T or YY/T status change, material product change, clinical-result release, or data/ethics-rule change.
Method and Complete Sources
Fact Additional complete-source entries used in this edition are the BCI research ethics guideline S0164, MIIT/TC4 establishment S0172, BCI industry implementation opinions S0173, innovative-device special review procedure S0190, and the Standardization Law S0210.
Fact This controlled edition uses the report evidence ledger, records legal effect and access limitations, retains official URLs and lawful mirrors for NMPA 412 conditions, and does not fabricate downloads. Complete cited source set: S0037, S0170, S0171, S0188, S0189, S0194, S0195, S0204, S0205, S0206, S0207, S0208, S0209, S0211, S0212, S0213, S0214, S0215, S0216, S0217, S0218, S0219, S0220, and S0221.